UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029147
Receipt number R000033327
Scientific Title Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Date of disclosure of the study information 2017/09/30
Last modified on 2021/09/24 13:37:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Acronym

Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Scientific Title

Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Scientific Title:Acronym

Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Region

Japan


Condition

Condition

pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of neoadjuvant chemotherapy for borderline pancreatic cancer.
To verify proper regimen, administration period and predictive biomarker.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

R0 resection ratio

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Borderline resectable pancreatic cancer who are planning neoadjuvant chemotherapy with the following criteria

1)no gender
2)age over 20 years old
3)the patients who gained written consent by the patient's free will with sufficient understanding after receiving sufficient explanation for the participation of this study,

Key exclusion criteria

Patients judged unsuitable as research subjects

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroaki Nagano

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code


Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2264

Email

hnagano@yamaguchi-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroto Matsui

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code


Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2264

Homepage URL


Email

matsui-h@yamaguchi-u.ac.jp


Sponsor or person

Institute

Yamaguchi Pancreatic / Biliary Disease Study Group

Institute

Department

Personal name



Funding Source

Organization

Yamaguchi Pancreatic / Biliary Disease Study Group

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 09 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2017 Year 08 Month 01 Day

Date of IRB

2017 Year 08 Month 30 Day

Anticipated trial start date

2017 Year 09 Month 01 Day

Last follow-up date

2020 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

collecting information in routine practice of borderline resectable pancreatic cancer patient undergoing neoadjuvant chemotherapy, safety
and efficacy will be evaluated.


Management information

Registered date

2017 Year 09 Month 14 Day

Last modified on

2021 Year 09 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033327


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name